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Abstract
Freezers with biospecimen deposits became biobanks and later were networked at
the pan-European level in 2013 under the Biobanking and BioMolecular Resources
Research Infrastructure—European Research Infrastructure Consortium (BBMRI-ERIC).
Drawing on document analysis about the BBMRI-ERIC and multi-sited fieldwork with
biobankers in Spain from a science and technology studies approach, we explore
what biobanks are expected to do and become under the BBMRI-ERIC framework,
and how infrastructural transitions promote particular transformations in biobanking
practices. The primary purpose of biobanks in Europe is presented as being to
become mediators in contemporary biomedical research (global sharing nodes)
distribution, and distributed nodes of samples and their associated data. We argue
that infrastructural transitions are complicated and heterogeneous, giving rise to
unattended local concerns on adjusting their practices to fit into the BBMRI-ERIC
framework, even for non-members, as the case of Spain illustrates, where “old
practices” of collection and storage are questioned. In this article, we aim to
encourage qualitative studies to explore the lags between pan-European policies
and prospects, different contextual interpretations, and biobanking reconfigurations
as an opportunity to explore what that lag is made of (e.g. tensions with “old
practices,” unresolved conflicts with the national agendas, reservations on a possible
centralization of the biobanking practices by regional biobanks, lack of funding, etc.).
Such research could enrich not only policy guidance, but also the understanding of
technoscientific infrastructures’ scalability.
Keywords: Biobanks, Europe, Infrastructure, Global, Biomedical research, Mediator,
Spain, Network, Scalability, Science and technology studies (STS)
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Introduction
In the late 1990s, several countries started to establish “nationally delimited,
population-based genetic databases, more commonly known as population biobanks”
(Mitchell and Waldby 2010, 332). These biobanks were framed under the narrative of
national resources (Cambon-Thomsen et al. 2003) and population national branding
(Tupasela 2017b). Biobanks became national projects involving articulations between
the state, the public, the scientific community, and economic agents. The spread and
rise of national biobanks run chronologically and in parallel with the last phase of the
Human Genome Project (HGP), a large-scale biology project that has been considered
a transformative agent of biology and medicine throughout a “big science” approach
(Collins et al. 2003; Hood and Rowen 2013). In April 2003, at the completion of the
HGP and the start of the referred to as the post-genomic age (Gottweis and Lauss
2010), a benchmark for “thinking bigger,” which is inseparable from bioresearch and
thus from biobank projects, had germinated. “Thinking bigger” can be understood as
the result of a shift in biological research to examining the larger picture in order to re-
search “what life is: the mechanisms, pathways, and systems” (Hadley 2004, 236), and
discerning complex connections that, on a smaller scale, could not be detectable. A glo-
bal competition within pharmacogenomics has also encouraged this way of “thinking”
(Pálsson 2007), and has furthered a commercial imperative for these projects. A part of
“thinking bigger” in biomedical research draws upon human biospecimen repositories,
such as biobanks, whose procedures called for harmonization to allow the general use
of samples, their associated data, and the services required to ease the post-HGP bio-
medical research.
On this matter, it is important to note that biobanks as national projects were
formally established right on the edge of the 20th to the twenty-first century, in a time
when the previous frame of the “taken-for-granted” (Wynne 2007) trust in Science,
with a capital S (Latour 1999), was questioned. Indeed, expectations linked to biobanks
gave rise to ambiguities and uncertainties (Stephens and Dimond 2015; Tutton 2010),
conceptualizing them as ethical problems (Hoeyer 2008), and, as such, biobanks were
framed under the ELSI (ethical, legal, and social issues) agenda. As other scholars have
noted (Balmer et al. 2015), the ELSI framework tends to bifurcate realities, “splitting-up
systems of reality” (Whitehead 2006) such as science and society. In biobanking, ELSI
approaches mainly revolve ethics challenges regarding donors (Kasperbauer et al. 2018;
Ursin and Stuifbergen 2018), informed consent (Boniolo et al. 2012; Kaye et al. 2015),
legislative frameworks for sample and data use (Zika et al., 2008), donors’ attitudes and
participation (Lipworth et al. 2011; Bossert et al. 2017), etc. But, as Cadigan et al.
(2013) noticed, pay little attention to biobankers practices and perspectives.
Terminology varies when referring to biomedical depositories where “bio” samples
are stored: repositories, biorepositories, collections, banks, cryobanks, biobanks, etc.
According to Tsing (2015, 29), “to use category names should be a commitment to
tracing the assemblages in which these categories gain a momentary hold”. So, it was
during the second half of the 1990s when the term “biobank” started to be used as the
preeminent reference to human-based repositories that collected and stored human
biospecimens and their associated data. Biobanks can be classified in different ways
based on tissue type, purpose, ownership, group of participants, or size (Arampatzis
et al. 2016). While there is a general shared picture of what a human-based biobank is,
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definitions in academic papers, guidelines, and policy reports are wide, varied, and
nuanced (Milanovic et al. 2007; Hewitt and Watson 2013; Shaw et al. 2014). Mayrhofer
(2011) asserted that the term “biobank” is an umbrella term, but others have suggested
that the concept of a “biobank” might be too singular (Hoeyer et al. 2017). The
approaches, in all their diversity, seem to recognize the complexity and hybridity of the
forms involved in biobanking (Romero-Bachiller and Santoro 2018; Tupasela et al.
2017). Tsing (2015, 293) explained, “[I] need names to give substance to noticing, but I
need them as names-in-motion.”
However, harmonization processes and procedures allowed the transformation of
researchers’ fridges or hospital anatomical pathology deposits into the technoscientific
infrastructures we call biobanks, which later would be proposed to become virtually
networked by the European Commission in 2013 as the Biobanking and BioMolecular
Resources Research Infrastructure—European Research Infrastructure Consortium
(BBMRI-ERIC). This pan-European initiative placed biobanks “in a process of transition
from individual research tools to complex international research infrastructures. This
process is not an ordered and homogenous change, but rather a complex and problem-
atic transition” (Meijer et al. 2012, 497). Scholars studying infrastructures have noted
(Harvey et al. 2016) that a linear development cannot be assumed. Infrastructural
politics generate complications as are shaped by multiple and distributed interactions,
and so do infrastructural transitions. There are some complications that highlight the
relevance of Tupasela’s (2017a, 190) observation: “There is a need to develop a more
nuanced theory of biobanking politics, where the interests of scientists who control
samples and data are better understood and recognized in relation to the more norma-
tive political expectations associated with sample-and data-sharing set out in polices.”
In this paper, following a science and technology studies (STS) approach, we point to
how these infrastructural transitions and their complications take part in biobanks’
social worlds, conceptualizations, and practices. We aim to promote further inquiry
into how situated reconfigurations in biobanking might note a lag with the policies and
prospects at the pan-European level, and explore what the lag is made of in different
contexts (e.g. tensions with “old practices,” unresolved conflicts with the national
agenda on biobanking, reservations on a possible centralization of the biobanking
practices by regional biobanks, etc.).
Assuming that “[t] he question ‘what is infrastructure’ must therefore be addressed,
and experimented with, in registers at once conceptual and empirical” (Harvey et al.
2016, 6), our inquiry combines both, but it stems from our fieldwork about biobanking
in Spain, which is focused on the practices and concerns of staff in different Spanish
biobanks. We identified a strong presence of the BBMRI-ERIC, despite Spain’s not
being a member of such infrastructure (as of June 2020). Therefore, we decided to
develop a document analysis to explore how biobanks are conceptualized by exploring
what they are meant to do at the pan-European level as presented in science policy
prospects and reports. Next, following Spanish biobankers’ aspirations to be part of the
BBMRI-ERIC, we show how reconceptualizing biobanks to fit under the pan-European
framework is translated into tension with “old practices,” in particular regarding the
collection, storage, and stockpiling of samples. We argue that greater attention and
qualitative research focusing on biobankers practices and country-specific concerns are
needed in combination with scrutinizing policy documents to identify and to describe
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unattended interpretations, shifts, and parallelisms between pan-European policy
prospects on infrastructures and their doings at different levels.
Materials and approach
The argument of this paper is based on two sources of data: qualitative fieldwork and
documents. We draw on 16months of multi-sited fieldwork, between 2018 and 2019,
with biobank staff in Spain,1 including participant observation in workshops, confer-
ences, newspaper follow-ups, and 14 semi-structured interviews with biobankers from
seven different biobanks that lasted between 45 min and 2 h. We interviewed biobanks’
directors, lab technicians, administrative staff, researchers, security guards, to explore
their perspectives and practices. We tape-recorded and fully transcribed 12 interviews.
The other two interviews were not fully-transcribed. Two interviewees did not allow us
to tape-record the interview (both of them biobank directors). One of these two did
not allow us to quote the content of his interview, following the informed consent opt-
out options. In these two cases, we took notes. We omitted the biobanks’ names and
specific locations, and assigned pseudonyms to the interviewed personnel, keeping only
their professional status to situate their comments in the context of their positions. In
our qualitative fieldwork and documentation of the Spanish context, the BBMRI-ERIC
appears as a milestone to reach, an institutional aspiration, and a model to conceptualize
and to articulate biobank practices. Therefore, considering our findings, we decided to
approach the BBMRI-ERIC through document analysis to better understand the current
state of affairs at the pan-European level, to see how biobanks’ primary purpose is formu-
lated and presented in such documents under the infrastructure that Spanish biobanks
take as a reference.
We reviewed documents dating from 2002, when the European Strategy Forum on
Research Infrastructures began, to the current day (early 2020). For the first period
(2002–2013), analysis was primarily based on two reports, the “Biobanks in Europe:
Prospectives for Hamornisation and Networking” (2010) by the JRC of the European
Commission and “Biobanks for Europe: A challenge for governance” (2012) by the
Directorate-General for Research and Innovation. We also consulted Community
Research and Development Information Service (CORDIS)2 reports and publications
regarding the Seventh Framework Programme for Research and Technological Devel-
opment (FP7) between 2007 and 2013, and Reports on the European Strategy Forum
on Research Infrastructures (ESFRI). For the second period (2013–2019), we incorpo-
rated BBMRI-ERIC documents, such as annual reports, statutes, deliverable reports,
press releases, Biobanks Europe Magazine, and newsletters. For the matter of this
paper, the focus is placed in the second period, 2013–2019. In the following section we
explore how biobanks are presented under the BBMRI-ERIC. Considering the way the
BBRMRI-ERIC assemblage is presented (and thus biobanks) has crucial implications
because, as Puig de la Bellacasa (2011, 87) put it, “how we present things matters.”
1Quotes from interviews and documents in Spanish have been translated by the authors.
2CORDIS is the European Commission’s primary public repository and portal to disseminate information on
all EU-funded research projects and their results.
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Scaling up biobanks: the BBMRI-ERIC
The European Strategy Forum on Research Infrastructures (ESFRI) was set up in
2002 following an EU Council call to support and encourage multilateral projects
in the EU and internationally, aiming to develop and improve different research in-
frastructures. Since then, the ESFRI roadmap has been brought up to date in 2008,
2010, 2016, and 2018, and it is expected to be updated in 2021. In this context,
the BBMRI-ERIC, as one of the projects within the pan-European research infra-
structures’ strategy in the 2006 roadmap began its preparatory phase in 2009 and
ran until 2011. During this phase, in 2010, the JCR Scientific and Technical Report
published “Biobanks in Europe: Prospects for Harmonisation and Networking.” This
report served as a call for attention for what was yet to come in biobanking, as
well as a formal recognition of the overwhelming harmonization challenges to be
faced not only at the pan-European level but also at the national and regional
levels, as other researchers have addressed (Chadwick and Strange 2015). The
BBMRI-ERIC acquired its legal status in 2013 and, as of June 2020, includes
sixteen full member states and four observers. The main goal of the BBMRI-ERIC
is described in its Statutes as follows:
BBMRI-ERIC shall establish, operate and develop a pan-European distributed
research infrastructure of Biobanks and Biomolecular Resources in order to
facilitate the access to resources as well as facilities and to support high quality
biomolecular and medical research. (BBMRI-ERIC 2016, emphasis added)
Scholarly publications have followed the establishment of the BBMRI-ERIC’s announ-
cing its potentialities as “a resource for pharmaceutical and life sciences industries”
(Van Ommen et al. 2015), a gateway to access collections for the European research
community (Mayrhofer et al. 2016), and the “[l] aunch of an infrastructure for Health
Research” (Litton 2018). Other scholars have focused on analyzing the challenges faced
during the preliminary phase (2009–2011). For instance, Tamminen (2015) identified
two key challenges in that period: first, mapping existing biobanks and second,
concerns related to language harmonization, which led to the creation of a “lexicon for
global biomedical research.” The establishment of the BBMRI-ERIC and networking
biobanks at the pan-European level requires changing some of the ways that biobanks
used to work, involving a complicated transition (Meijer et al. 2012) and exacerbation
of already existing governance challenges.
Overall, the BBMRI-ERIC intends to integrate already existing research infrastruc-
tures and research communities from the field of life sciences in Europe, taking advan-
tage of information systems and boosting biobanks’ capabilities for biomedical and
drug research. Bioinformatics’ combination of molecular biology investigation and com-
puter science has promoted an emergent way of understanding diseases that depends
upon infrastructures that build and maintain large-scale networks of databases, estab-
lishing and integrating research infrastructures for the “virtualization of biological work
and biological objects” (Stevens 2013). From the scientific community perspective,
thicker networked infrastructures are crucial in order to use the biomedical capabilities
that biobanks can provide for what is often referred to as “precision medicine” as well
as for research on biomarkers and their resulting potential treatments.
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The BBMRI-ERIC does not consist of the establishment of a new physical European
biobank, but the creation of an active network among existing biobanks and biore-
sources. Network membership requires an economic contribution by the member state,
and then, each member state designates a national node that will coordinate the exist-
ing biobanks in that country to scale-up their bioresources to the pan-European level.
This network brings forth tools such as the BBMRI-ERIC directory, which enables
searches of the bioresources of European biobanks by applying several search filters
and variables. Expansion occurs through scale-up, as in many other capitalist processes
(Tsing 2015), scalability is at stake. Still, the success of scalability or the possible leaks
and failures call for situated research at the national and sub-national levels to account
for “the links between the scalable and nonscalable” (Tsing 2012, 154).
Scaling up digitally as opposed to the creation of a bigger physical enterprise can be
addressed in its specifics through the scaling dynamics identified by Sassen (2007)
regarding global digital formations and Tsing’s (2012) nonscalability theory. The
BBMRI-ERIC infrastructural assemblage gathers features that characterize what Sassen
(2007) calls the “networked sector,” while simultaneously undergoing deterritorializa-
tion and territorialization processes that feed on each other. Harmonized procedures
and digital directories may work as critical hinges here, allowing integration, contrac-
tion, and expansion as much as deterritorialization and territorialization. Tsing’s non-
scalability theory proposes that “instead of taking scalability for granted as a necessary
tool of progress, nonscalability theory attends to the work of contingency and failure.
Nonscalability theory shows us scalability in action” (Tsing 2012, 148). Therefore,
scaling up cannot be approached as an inevitable occurrence, but an ongoing work that
generates numerous frictions. We will exemplify one of such frictions further on re-
garding biobanking practices in Spain, but before this, let us explore biobanks under
the BBMRI-ERIC framing.
Biobanks as mediators
The BBMRI-ERIC case provides a set of practices, proposals, and expectations to help
readers grasp what biobanks are meant to do in Europe. This particular infrastructure
reveals an effort to digitally harmonize and integrate different biobanks. According to
Article 1 of the BBMRI-ERIC’s Statutes (2016) biobanks, in plural, are “collections,
repositories and distribution centers of all types of human biological samples … and/or
related data … contribute to the understanding of the physiology and diseases of
humans.” Under this infrastructure, integration aims to facilitate sharing bioresources,
such as biospecimens and associated data, that are expected to contribute to biomedical
research and clinical care, rather than being banked in aetérnum. Taking care of a bios-
pecimen implies making it available in its best quality (i.e., the sample and its associated
data) and for this, the BBRMRI-ERIC provides the infrastructure to scale-up biobanks
by creating a federated network.
Hoeyer et al. (2017, 388) observed that “the concept of ‘biobank’ might be too singu-
lar (one set of samples in one place), too static to capture the sense of flow (it indicates
accumulation), and too informed by one type of purpose (research) to capture all the
involved flows and uses”. Paying attention to flows requires to be aware that flows
preceded the assemblage, albeit without the formal infrastructure required in order to
be used efficiently, which is precisely the aim of the BBMRI- ERIC. Star and Ruhleder
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(1996) explained that infrastructures aim to resolve the tension between the local and
the global, and, to do so, connections are made, for instance, through bioresource
directories. When scaling-up digitally, the connections involved in this practice make
infrastructures pop-up, or become visible. Connections are also stressed in the BBMRI-
ERIC Report (BBMRI-ERIC 2013, 22) where it is said that biobanks are expected to act
as an “intermediary” between donors/participants, scientists, patients, hospitals, and so
on. If recognition of biobanks’ mediator position is central to reaching their purpose,
increasing their visibility becomes a need in order to make the assemblage work. For
this reason, it was not surprising to read while writing this paper that the title of the
current Action Plan of the BBMRI-ERIC 2019–2021 is “increasing the visibility of
biobanks and sample collections” (BBMRI-ERIC 2019).
However, intermediary is not an innocent term. STS scholars are wary of the differ-
ences and nuances between intermediaries and mediators (Serres and Latour 1995;
Latour 2005). Is biobanks’ only purpose to allow access to samples and data or do they
also redefine what they collect and share? An intermediary, according to Latour (2005,
39), “transports meaning or force without transformation”, working as a black box or a
unit; while mediators are “endowed with the capacity to translate what they transport,
to redefine it, redeploy it, and also to betray it” (Latour 1993, 81). Mediators can betray,
but also care. In fact, biobanks tend to be endorsed as caretakers of the samples and
their associated data. Biobanks’ curating practices and knowledge production on
biospecimens shape and redefine how science is made.
As mediators and not mere intermediaries, biobanks in the BBMRI-ERIC network
express the aforementioned “thinking bigger.” In this case, “thinking bigger” does not
entail “making it bigger” as in physics (Vermeulen 2016), like in the case of the Large
Hadron Collider, but doing it bigger by digitally scaling up infrastructures, collabora-
tions, and networked services. Connections are what enable this “thinking bigger” and
make it global (Serres 1994). Biobanks act as mediators when their central purpose is
to distribute samples and their associated data, instead of just accumulating them. Re-
garding biobanks as mediators, we have identified three different practices that
characterize biobanks under the BBMRI-ERIC logic: globalizing, sharing, and localizing.
Globalizing
Globalizing is made of connectivity and virtualization. The pan-European network of
biobanks builds on the connection of several distributed infrastructures, bearing upon
directories, datasets, freezers, samples, computers, workers, lab devices, donors/partici-
pants, etc. Indeed, it is this infrastructural assemblage that enables multiscalar practices
and global effects. We can describe, thus, how fridges in offices and hospitals were
compiled and relocated to a common space with other freezers, which were connected
to computers and registries of digitized data. Informatics capabilities, standards, and
harmonization processes enabled a network of freezers with biospecimens and their
associated data, but also a network of infrastructural labor. Connections are what make
the network global (Serres 1994).
Additionally, biobanks in Europe through the BBMRI-ERIC brought about a process
of virtualization. According to Lévy (1998, 29), virtualization is based on a breakdown
of spatiotemporal coordinates, “incorporating temporal unity without spatial unity”.
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This breakdown does not make spatiotemporal coordinates fully independent because
they still bond to the physical; virtualization does not entail disappearing or
dematerialization (Lévy 1998). Hence, we approach global in the sense of generative
connections rather than as a universal or territory-based conceptualization. Collier and
Ong (2005, 11) have posited that global phenomena “have a distinctive capacity for
decontextualization and recontextualization, abstractability and movement, across
diverse social and cultural situations and spheres of life”, and so do these networks.
Sharing
The goal of collecting samples and their associated data under high-quality standards
aims to engender and distribute the best quality biospecimens and associated data
(bioresources) for biomedical research projects. This emphasis on “quality” here is
mainly a focus on enabling replicability, and for that end, work is needed to ensure
that, as Tarkkala (2019, 36) has also observed, “the samples stored should be what they
are said to be”—something that has not been that mundane or common. Sharing, and
not banking as accumulation, involves paying greater attention to what is presented as
biobanks’ current main function: visible–physical recipients of biospecimens. And, yet,
also abstract mediated data-transmitters that enact bioresources’ mobilities. In biobank-
ing, biospecimens are samples, but they are also meta-data: “biological exchanges [that]
informationalize without dematerializing” (Thacker 2005, 11). Milanovic et al. (2007)
analyzed the plurality of exchange regimes present in biobanking, which we acknow-
ledge, but for this paper, we have decided to use the word sharing instead. While the
word “exchange” tends to refer to a more evident bidirectional relationship, in biobank-
ing, the relationships consist more of gift-giving, which engages with highly mediated
modes of reciprocity. The BBMRI-ERIC report reads:
Typically, biobanks are viewed as a “public good”: a shared resource to which
individuals contribute through their blood donations and that will, eventually,
result in a reciprocal benefit in the form of better and more effective medical
treatment options. (BBMRI-ERIC Report 2013, 38)
We propose to work with the word “sharing” as it better condenses the idea of the
action that takes place in biobank relationships, one with a less clear trajectory. In
addition, sharing often involves dividing things into portions,3 which definition better
relates to biobanking. This definition of “sharing” also makes explicit the logic of the
phrase, “sharing is caring,” as sharing is a way to take care of the sample—by making it
available for use. However, this logic also raises concerns. Therefore, we will not talk
about a vision of innocent and romantic share-care, as Puig de la Bellacasa (2011, 100)
notes: “a way of caring over here could kill over there.” Nonetheless, sharing is critical.
So we must turn to ask: Who shares what, for whom, and for what? Following the fea-
tures of digitally scaling-up biobanks, instead of creating a bigger biobank,
commensurability is put aside in this reflection. Biospecimens and their associated data
become singularities of a “troubling multiplicity of instances” (Strathern 2004).
3The main entry of the verb share in the Oxford Dictionary reads: “have a portion of (something) with
another or others.” Two sub-entries refer to it but with other verbs such as give, use, occupy, and enjoy
(something). Oxford Dictionary Online: https://www.lexico.com/en. Accessed 28 August 2019.
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Localizing
Globalizing and sharing evoke images of centrifugal forces, yet biobanks’ materiality
matters. Therefore, we also recall centripetal forces, approaching them as localizing
practices. Contrasting with the virtualization of samples and sharing practices, we take
as a reference Kaye’s (2011) conceptualization of biobanks as nodes, from which data
flows internationally through local researchers and institutions. Node implies an
anatomic differentiated material mass—for instance, biobanks’ deposits, lab gloves,
computer servers, and the material form of biospecimens are the aspects that can be
readily differentiated from the whole research infrastructure or the imbrication. The
anatomical allusion behind the notion of node provides physicality and avoids
approaching digitization as lacking materiality. Also, biobanks in the BBMRI-ERIC
infrastructure and framework compare favorably with other uses of the global node
concept, such as Harvey’s (2007) use of the concept nodes in a global network in the
case of the London Gold Fix, as an active and essential local connecting point. Nodes
localize materials and ways in which others care, as much as they generate “matters of
concern” (Latour 2004) regarding national jurisdictions, data privacy, replication con-
troversies, etc. Without lab technicians processing the samples, server stations, office
workers at the donor call centers, or security personnel attending around the clock to
beepers connected to the frozen deposits, there is no biobank nor, hence, a network of
biobanks. However, it is necessary to note that the BBMRI-ERIC defined the entities that
coordinate biobanks in different countries as nodes and not biobanks themselves. There-
fore, this analysis does not follow the BBMRI-ERIC use of the term but plays with it.
Following our analysis of the BBMRI-ERIC, we have engaged in an exercise of
creating a compound noun as a descriptive device that will contribute to a better
understanding of biobanks in the current European context. We take Kaye’s (2011)
proposal of defining biobanks as nodes, but we go a step further, defining a biobank as
a node of a global network—a global sharing node. This reflective proposal avoids the
commensurability attached to other adjectival word choices such as “large-scale” or
“big.” In this compound noun, size is set aside but not disregarded and, instead, we
emphasize multiscale mobilities and localities, scalability and nonscalability. The term
global sharing nodes accommodates current biobank practices and enables readers to
grasp what biobanks are presented to do and become after the establishment of the
BBMRI-ERIC infrastructure in Europe. Situating biobanks in the network as global
sharing nodes is an exercise that purports to indicate their reconfigurations, after the
establishment of the BBMRI-ERIC in 2013.
The nodes to be: parallelisms, reconfigurations, and aspirations from Spain
In Europe, biobanks’ governance, organizational features, and funding actors vary in
every country (Meijer et al. 2012). In the case of Spain, biobanks are under the um-
brella of the Spanish National Healthcare System’s strategic agendas for the promotion
and improvement of universal and public healthcare. Indeed, the Royal Decree 1716/
2011 that specifically legislates biobanks highlights their “public service vocation,”
whose base is to provide quality samples to the scientific community. The Spanish
Biobank Network (RNBB) was created in 2009, and between 2011 and 2013 the major-
ity of biobanks were formally established and registered, following the aforementioned
decree. Indeed, 88 out of 99 biobanks were registered in the National Registry of
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Biobanks (as of July 8, 2020) before 2014. Currently, the Spanish Biobank Network in-
cludes hospital-based biobanks, regional networks, research institutes, and university
biobanks from all over the country. The efforts of the national network in its first
decade have been placed on working in a coordinated but decentralized manner, and in
the creation of a sample catalog and a unique window for sample requests.
Despite Spain’s not being a member of the BBMRI-ERIC, the timeline of biobanks’
establishment runs in parallel with that of the BBMRI-ERIC at the pan-European level.
These parallelisms and presence can be tracked prior to 2013 when the BBMRI-ERIC
acquired its legal status. In 2010, one of the principal representatives of the biobanking
community in Spain participated in the BBMRI Stakeholder’s forum (2010), and in July
2020, if you check the Spanish Biobank Network Wikipedia entry “vision and mission”
(whomever has edited it) states that it has a similar design to the preliminary BBMRI
project. We have already pointed to how the BBMRI-ERIC Report (2013) situated
biobanks as “intermediary agents,” a position that is currently mirrored in Spain. In
February 2020, the Spanish New Medical Economics Journal published “Biobanks:
Connectors between patients, researchers, and physicians.” Therefore, we argue that
the BBMRI-ERIC has been serving as a model for conceptualizing biobanks’ work and
reconfiguring their practices since their formal establishment in Spain. But, how is the
BBMRI-ERIC interpreted, and why is it important to be part of it from the biobankers
perspective? Which implications entail making biobanks become global sharing nodes
for biobankers practices?
During fieldwork, biobankers made explicit that being part of the BBMRI-ERIC is
something they have requested for a long time, but that it has been postponed due to
the membership fees required to become a member. After the 2018 IX Spanish
National Conference of Biobanks, media reported that for the biobanking community
in Spain, the way to fit into the BBMRI-ERIC was “the principal challenge of the future,”
as pointed by the president of the biobanks’ scientific committee during the 2018
conference. The headlines of some newspapers’ editorials in the autumn of 2018 wrote:
“Spanish biobanks search how to fit into a European structure” (Diario Médico,
November 18, 2018) or “Spanish biobanks are looking forward to being part of the
primary European network” (La Vanguardia, November 18, 2018). Considering that the
BBMRI-ERIC presents biobanks as global sharing nodes, this notion of “how to fit” in
Spain has turned into working on the coordination of the national network, but also it has
highlighted concerns regarding the underuse of samples due to “old practices” on collec-
tions, storage, and stockpiling. Therefore, the BBMRI-ERIC serves as a classical “Europe-
is-the-solution” kind of argument (Gasset in Narotzky 2016) for Spanish underfunded
technoscientific infrastructures, but also it provides a platform for collaborations, and
therefore for the use of stored samples.
In general, one can easily see how many samples have been transferred for research
by a particular biobank or a total calculation gathered by the national network (as of
July 8, 2020, the Spanish Biobank Network website announces that 629,592 samples
have been transferred by the network). Yet, the rotation rate, the number of samples
collected and transferred per year are not that transparently publicized nor easy to ac-
cess. Indeed, we were unable to collect such data in most of the cases. We understand
the reasons that might be behind these strategic decisions. Indeed, the underuse of
biospecimens has also been pointed to as a neglected issue in biobanking in other
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contexts (Cadigan et al. 2013; Stephens and Dimond 2015). However, during fieldwork,
we found that biobankers did not neglect this issue. In an interview with a biobank re-
searcher and administrative staff from one of the biggest biobanks in Spain, they ex-
plained that stockpiling samples of rare diseases is justified due to scarcity logic, but
not necessarily in other cases. As an example of the current discussions among bioban-
kers in Spain, we present the following excerpt:
– “A register (of potential donors) makes the biobank more sustainable” says Pedro, a
biobank researcher. “This way, you can identify potential donors of samples for
biomedical research. Then, when there is a project request, you know the specifics
of the sample and the format you need, instead of storing samples without knowing
what purpose they will be used for. This way, you avoid having thousands of
samples in the freezer. Storing samples means that some can be damaged, can fall
…”
– “Or that they (samples) will never be used,” intervenes Juana, administrative staff
from the biobank.
– “Right, that is also what I mean when I refer to the biobank’s sustainability,” points
out Pedro.
– “But do biobanks store a lot of samples? I thought the main purpose was to make
them available for research, to be used in biomedical research projects,” the
interviewer asks.
– “I remember a rotation index from a few years ago … and the majority of the
samples were not getting out, and you cannot store them forever and ever. At some
point you need to stop … [i] t is impossible to maintain a biobank if 90% of the
samples become stock. It should be the other way around—10% stock and 90%
transfers,” answers Juana. (Interview, October 2018)
What the interviewees discussed is how the storage and stockpiling of samples, which
has been portrayed as the primary function of biobanks, do not necessarily facilitate
biobanks’ main purpose today as distributors of samples, as global sharing nodes. This
tension cannot simply be answered under scarcity or a selfish logic. Instead, what the
interviewees are explaining is that if biobanks aim to become distributors of samples
rather than warehouses or underused libraries, then, sample collection needs to be
reconfigured. Switching to a prospective collection of samples (when possible) for
specific projects would reduce stock, as Pedro explained. Thus, the how, what, and
when to store become basic and relevant questions to be formulated in order to
promote anticipation or preparedness, rather than banking and waiting for a hypothetic
future use. This shift requires a reconfiguration of the “old practices” (hoarding sam-
ples) that have characterized biobanking, at least in Spain.
The excerpt summarizes what biobanks are no longer for Spanish biobankers, and
shows the emergence of infrastructural complications: on one side, the practice of stor-
ing/banking is under scrutiny, and thus biobanks’ main function is also; on the other
side, a registry of potential donors of biobank samples is presented as a possible mech-
anism to reduce the underuse of samples. Data accumulation is then presented as a tool
for biobanks’ sustainability. We observe that while data follows a logic of accumulation
(Hoeyer 2018), in this case, it takes the form of a registry of potential donors,
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biospecimens do not necessarily follow this rationale. Sorting out how to become global
sharing nodes mirroring the BBMRI-ERIC in the Spanish context is entangled with re-
configuring banking practices to address the underuse of samples, among other things.
However, reconfiguring biobanks’ practices might vary cross-nationally from non-
members of the BBMRI-ERIC. For example, a visit to the coordinator center of the
Danish National Biobank or/and a consult of their website shows that sample accumu-
lation and storage is at the forefront. Therefore, not all countries in Europe might be
interpreting becoming global sharing nodes in the same way. And, not all biobanking
communities might even be committed to fitting under the BBMRI-ERIC prospects.
Conclusions
Freezers and deposits with samples became biobanks and later were called to be net-
worked at a pan-European level to expand their potential as distributors of samples and
their associated data. Sample and data collection, biospecimen science, the curation of
the sample, and—most importantly—making these bioresources available for biomed-
ical research are some of the practices involved in biobanking. Biobanks’ promises and
expectations as caretakers of human biospecimens and their associated data are related
to a particular understanding of diseases and treatment development, such as how
medicine and healthcare are framed in a specific moment and context. Biobanks’
virtualization or data-sharing emphasis is part of a broader framework in which
“thinking bigger” in the life sciences and precision medicine are conceived mainly as
data-driven medicine (Prainsack 2017). Thus, contemporary biobanks under the
European framework are mediators for biomedical research, engendering and articulat-
ing particular modes of reciprocity, knowledge production, and forms of “biovalue”
(Waldby 2000).
Infrastructural transitions have implications on how biobanks’ purpose is presented,
and therefore, is transformed or how their practices are put in question. In Europe, these
transformations are led by the BBMRI-ERIC, which policy prospect connects biobanks
at a pan-European level, as a “networked sector,” re-articulating biobanks challenges and
practices. We identified that the establishment of this infrastructure highlights biobanks
as mediators between researchers, patients, hospitals, physicians, and so forth. Three
practices summarize how the BBMRI-ERIC scales-up biobanks as mediators: globalizing,
sharing, and localizing. We proposed that this is best expressed through the compound
noun global sharing nodes: Global, as made by connectivity and virtualization; sharing,
to look at the main expected action; and nodes, to stay with biobanks’ materiality and
local practices. Tracking what biobanks are expected to be and do, also indicates what
are not supposed to do and be any longer. Biobanks’ transformations under the BBMRI-
ERIC framework have implications even for non-members, as we have shown in the
Spanish case. Does the establishment of the BBMRI-ERIC have a presence in other non-
members states? If so, with what implications or interpretations? And among current
members, what do members of the BBMRI-ERIC do in practice?
In Spain, where the biobanking community aspires to be part of the BBRMI-ERIC,
biobank practices are called to be transformed to better fit in what biobanks are ex-
pected to do nowadays. We incorporated this particular case to show a lag between
biobanks’ policy framework prospects at the pan-European level, and interpretations
and infrastructural complications regarding biobanks’ old practices, that is, what
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scalability entails. A grounded guidance at the policy level on how to transition towards
becoming global sharing nodes is needed in order to address local concerns on the
emergence of biobanks’ infrastructural and economic fragilities under this passage, as
the example of the personnel concern on biospecimen underuse and the reconsider-
ation of storing practices illustrate. In this regard, empirical qualitative research on the
lags between pan-European policy prospects and biobanks’ transformations in different
contexts are highlighted as valuable in understanding not only these infrastructural
transitions but also scalability in contemporary technoscientific projects.
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